Free Trial

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical logo
$84.55 +0.96 (+1.15%)
(As of 02:20 PM ET)

Globus Medical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
8

Based on 12 Wall Street analysts who have issued ratings for Globus Medical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 3 have given a hold rating, and 8 have given a buy rating for GMED.

Consensus Price Target

$88.18
4.30% Upside
According to the 12 analysts' twelve-month price targets for Globus Medical, the average price target is $88.18. The highest price target for GMED is $100.00, while the lowest price target for GMED is $78.00. The average price target represents a forecasted upside of 4.30% from the current price of $84.55.
Get the Latest News and Ratings for GMED and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Globus Medical and its competitors.

Sign Up

GMED Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$88.18$77.78$77.00$65.11
Forecasted Upside4.30% Upside6.02% Upside6.87% Upside41.64% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

GMED Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMED Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Globus Medical Stock vs. The Competition

TypeGlobus MedicalMedical CompaniesS&P 500
Consensus Rating Score
2.58
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside5.51% Upside26,931.57% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent GMED News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Morgan Stanley
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$74.00 ➝ $83.00+2.62%
11/6/2024Roth Mkm
1 of 5 stars
 Reiterated RatingBuy ➝ Buy$100.00 ➝ $100.00+23.38%
11/6/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$79.00 ➝ $85.00+4.87%
11/6/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$80.00 ➝ $92.00+13.51%
11/6/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$80.00 ➝ $92.00+13.12%
11/6/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Chopra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$78.00 ➝ $88.00+8.92%
11/6/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. O'brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$80.00 ➝ $100.00+32.29%
11/6/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
11/6/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$55.00 ➝ $80.00+5.83%
10/14/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$77.00 ➝ $78.00+10.03%
8/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$85.00 ➝ $93.00+26.00%
8/7/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$78.00 ➝ $79.00+14.48%
2/10/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$90.00 ➝ $70.00+11.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:40 PM ET.


GMED Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Globus Medical is $88.18, with a high forecast of $100.00 and a low forecast of $78.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMED shares.

According to analysts, Globus Medical's stock has a predicted upside of 4.30% based on their 12-month stock forecasts.

Analysts like Globus Medical less than other "medical" companies. The consensus rating score for Globus Medical is 2.58 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GMED compares to other companies.


This page (NYSE:GMED) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners